The addition of DelOrefice, who serves as CFO at BD, expands the ResMed board to 11 total directors. His appointment goes into effect immediately, and he will stand for re-election with the rest of the board at the company’s Nov. 21 annual meeting. DelOrefice also joined the audit committee of the board for the sleep apnea therapy maker.
DelOrefice has more than 30 years of experience in audit, finance and strategic roles. He became BD’s CFO in September 2021. Before that, he served in a number of roles at Johnson & Johnson, including VP of investor relations. He also held the post of CFO for J&J’s consumer and medical devices business segments for North America.
Prior to J&J, he held positions of increasing responsibility at AstraZeneca, AET Films and Ametek.
“I’m pleased to welcome Christopher DelOrefice to ResMed’s board,” said Mick Farrell, chair and CEO of ResMed. “Chris has proven himself an experienced global leader in corporate finance and business strategy, as well as in global operations management across multiple business sectors, including in his current role as CFO of a multi-billion dollar, global medtech company. My fellow board members and I were impressed with Chris’ achievements, as well as his humility, hard-working nature, and leadership capabilities, all of which are highly relevant to his service as a ResMed director. Chris’ financial experience in healthcare and medical technology at BD, J&J, and AstraZeneca will complement the leaders already serving as ResMed directors.”
